There are some strong arguments for revoking Myriad's patent. One is that a component of the human body—life itself—cannot and should not be commodified. Another is the sound technical argument that testing for mutations by doing full sequencing rather than comparing particular strains is more accurate, which means the use of Myriad's patented test impedes both research and treatment. But if the EPO or another agency revoked Myriad's patent because it was deemed bad for the Jews, that would set a silly and dangerous precedent. The unfair-advantage-for-the-Jews claim comes fast on the heels of the anti-Semitism claim. Every advance in genetic medicine will benefit a particular ethnic group. It's in the genes.
TODAY IN SLATE
Don’t Worry, Obama Isn’t Sending U.S. Troops to Fight ISIS
But the next president might.
IOS 8 Comes Out Today. Do Not Put It on Your iPhone 4S.
Why Greenland’s “Dark Snow” Should Worry You
How Much Should You Loathe NFL Commissioner Roger Goodell?
Here are the facts.
Amazon Is Launching a Serious Run at Apple and Samsung
Slim Pickings at the Network TV Bazaar
Three talented actresses in three terrible shows.
More Than Scottish Pride
Scotland’s referendum isn’t about nationalism. It’s about a system that failed, and a new generation looking to take a chance on itself.